Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Balance Sheet
Balance Sheet Decomposition
Cumberland Pharmaceuticals Inc
Current Assets | 35.7m |
Cash & Short-Term Investments | 18.3m |
Receivables | 9.8m |
Other Current Assets | 7.6m |
Non-Current Assets | 46.1m |
PP&E | 7m |
Intangibles | 23.5m |
Other Non-Current Assets | 15.5m |
Current Liabilities | 28m |
Accounts Payable | 14m |
Accrued Liabilities | 348.1k |
Other Current Liabilities | 13.6m |
Non-Current Liabilities | 24.2m |
Long-Term Debt | 12.8m |
Other Non-Current Liabilities | 11.4m |
Balance Sheet
Cumberland Pharmaceuticals Inc
Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
40
|
38
|
35
|
45
|
28
|
28
|
25
|
27
|
20
|
18
|
|
Cash Equivalents |
40
|
38
|
35
|
45
|
28
|
28
|
25
|
27
|
20
|
18
|
|
Short-Term Investments |
15
|
15
|
16
|
5
|
8
|
0
|
0
|
0
|
0
|
0
|
|
Total Receivables |
6
|
6
|
7
|
8
|
8
|
10
|
12
|
7
|
13
|
10
|
|
Accounts Receivables |
6
|
6
|
7
|
8
|
8
|
10
|
12
|
7
|
13
|
10
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
6
|
4
|
5
|
7
|
12
|
9
|
11
|
8
|
10
|
5
|
|
Other Current Assets |
5
|
4
|
3
|
4
|
3
|
3
|
2
|
3
|
3
|
3
|
|
Total Current Assets |
71
|
67
|
66
|
69
|
59
|
50
|
50
|
46
|
46
|
36
|
|
PP&E Net |
1
|
1
|
1
|
1
|
1
|
4
|
3
|
1
|
6
|
7
|
|
PP&E Gross |
1
|
1
|
1
|
1
|
1
|
4
|
3
|
1
|
6
|
7
|
|
Accumulated Depreciation |
2
|
3
|
3
|
3
|
3
|
3
|
4
|
4
|
2
|
2
|
|
Intangible Assets |
22
|
21
|
22
|
21
|
34
|
31
|
28
|
24
|
31
|
23
|
|
Goodwill |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Other Long-Term Assets |
2
|
3
|
5
|
3
|
18
|
19
|
15
|
12
|
10
|
15
|
|
Other Assets |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Total Assets |
95
N/A
|
92
-4%
|
93
+2%
|
93
0%
|
113
+21%
|
105
-7%
|
97
-8%
|
84
-12%
|
93
+10%
|
82
-12%
|
|
Liabilities | |||||||||||
Accounts Payable |
3
|
3
|
8
|
9
|
11
|
12
|
13
|
10
|
11
|
14
|
|
Accrued Liabilities |
0
|
0
|
0
|
0
|
2
|
3
|
2
|
2
|
2
|
2
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
11
|
10
|
7
|
9
|
15
|
9
|
10
|
7
|
16
|
12
|
|
Total Current Liabilities |
14
|
12
|
15
|
18
|
28
|
24
|
26
|
19
|
29
|
28
|
|
Long-Term Debt |
0
|
2
|
4
|
10
|
20
|
19
|
15
|
15
|
16
|
13
|
|
Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
1
|
1
|
1
|
2
|
9
|
11
|
9
|
8
|
12
|
12
|
|
Total Liabilities |
15
N/A
|
15
+3%
|
20
+35%
|
29
+44%
|
57
+95%
|
53
-6%
|
50
-7%
|
42
-16%
|
57
+36%
|
52
-8%
|
|
Equity | |||||||||||
Common Stock |
62
|
57
|
55
|
52
|
51
|
50
|
49
|
48
|
47
|
47
|
|
Retained Earnings |
19
|
20
|
19
|
12
|
5
|
1
|
2
|
6
|
11
|
17
|
|
Total Equity |
81
N/A
|
77
-5%
|
73
-5%
|
64
-12%
|
56
-13%
|
51
-8%
|
47
-8%
|
43
-9%
|
36
-15%
|
30
-18%
|
|
Total Liabilities & Equity |
95
N/A
|
92
-4%
|
93
+2%
|
93
0%
|
113
+21%
|
105
-7%
|
97
-8%
|
84
-12%
|
93
+10%
|
82
-12%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
17
|
16
|
16
|
16
|
16
|
15
|
15
|
15
|
14
|
14
|